Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer

Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer

A randomized phase 2 clinical trial has recently shown no benefit of the combination eribulin and pembrolizumab over pembrolizumab alone in HR + metastatic breast cancer patients (NCT03051659). Here, the authors are reporting the final OS data and biomarker analyses on a subset of samples to analyze...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Tanya E. Keenan, Jennifer L. Guerriero, Romualdo Barroso-Sousa, Tianyu Li, Tess O’Meara, Anita Giobbie-Hurder, Nabihah Tayob, Jiani Hu, Mariano Severgnini, Judith Agudo, Ines Vaz-Luis, Leilani Anderson, Victoria Attaya, Jihye Park, Jake Conway, Meng Xiao He, Brendan Reardon, Erin Shannon, Gerburg Wulf, Laura M. Spring, Rinath Jeselsohn, Ian Krop, Nancy U. Lin, Ann Partridge, Eric P. Winer, Elizabeth A. Mittendorf, David Liu, Eliezer M. Van Allen, Sara M. Tolaney
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/d25f24d7eb06482f96ec27595b0111bc
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:d25f24d7eb06482f96ec27595b0111bc
record_format dspace
spelling oai:doaj.org-article:d25f24d7eb06482f96ec27595b0111bc2021-12-02T18:14:31ZMolecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer10.1038/s41467-021-25769-z2041-1723https://doaj.org/article/d25f24d7eb06482f96ec27595b0111bc2021-09-01T00:00:00Zhttps://doi.org/10.1038/s41467-021-25769-zhttps://doaj.org/toc/2041-1723A randomized phase 2 clinical trial has recently shown no benefit of the combination eribulin and pembrolizumab over pembrolizumab alone in HR + metastatic breast cancer patients (NCT03051659). Here, the authors are reporting the final OS data and biomarker analyses on a subset of samples to analyze molecular correlatesTanya E. KeenanJennifer L. GuerrieroRomualdo Barroso-SousaTianyu LiTess O’MearaAnita Giobbie-HurderNabihah TayobJiani HuMariano SevergniniJudith AgudoInes Vaz-LuisLeilani AndersonVictoria AttayaJihye ParkJake ConwayMeng Xiao HeBrendan ReardonErin ShannonGerburg WulfLaura M. SpringRinath JeselsohnIan KropNancy U. LinAnn PartridgeEric P. WinerElizabeth A. MittendorfDavid LiuEliezer M. Van AllenSara M. TolaneyNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-13 (2021)
institution DOAJ
collection DOAJ
language EN
topic Science
Q
spellingShingle Science
Q
Tanya E. Keenan
Jennifer L. Guerriero
Romualdo Barroso-Sousa
Tianyu Li
Tess O’Meara
Anita Giobbie-Hurder
Nabihah Tayob
Jiani Hu
Mariano Severgnini
Judith Agudo
Ines Vaz-Luis
Leilani Anderson
Victoria Attaya
Jihye Park
Jake Conway
Meng Xiao He
Brendan Reardon
Erin Shannon
Gerburg Wulf
Laura M. Spring
Rinath Jeselsohn
Ian Krop
Nancy U. Lin
Ann Partridge
Eric P. Winer
Elizabeth A. Mittendorf
David Liu
Eliezer M. Van Allen
Sara M. Tolaney
Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer
description A randomized phase 2 clinical trial has recently shown no benefit of the combination eribulin and pembrolizumab over pembrolizumab alone in HR + metastatic breast cancer patients (NCT03051659). Here, the authors are reporting the final OS data and biomarker analyses on a subset of samples to analyze molecular correlates
format article
author Tanya E. Keenan
Jennifer L. Guerriero
Romualdo Barroso-Sousa
Tianyu Li
Tess O’Meara
Anita Giobbie-Hurder
Nabihah Tayob
Jiani Hu
Mariano Severgnini
Judith Agudo
Ines Vaz-Luis
Leilani Anderson
Victoria Attaya
Jihye Park
Jake Conway
Meng Xiao He
Brendan Reardon
Erin Shannon
Gerburg Wulf
Laura M. Spring
Rinath Jeselsohn
Ian Krop
Nancy U. Lin
Ann Partridge
Eric P. Winer
Elizabeth A. Mittendorf
David Liu
Eliezer M. Van Allen
Sara M. Tolaney
author_facet Tanya E. Keenan
Jennifer L. Guerriero
Romualdo Barroso-Sousa
Tianyu Li
Tess O’Meara
Anita Giobbie-Hurder
Nabihah Tayob
Jiani Hu
Mariano Severgnini
Judith Agudo
Ines Vaz-Luis
Leilani Anderson
Victoria Attaya
Jihye Park
Jake Conway
Meng Xiao He
Brendan Reardon
Erin Shannon
Gerburg Wulf
Laura M. Spring
Rinath Jeselsohn
Ian Krop
Nancy U. Lin
Ann Partridge
Eric P. Winer
Elizabeth A. Mittendorf
David Liu
Eliezer M. Van Allen
Sara M. Tolaney
author_sort Tanya E. Keenan
title Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer
title_short Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer
title_full Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer
title_fullStr Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer
title_full_unstemmed Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer
title_sort molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer
publisher Nature Portfolio
publishDate 2021
url https://doaj.org/article/d25f24d7eb06482f96ec27595b0111bc
work_keys_str_mv AT tanyaekeenan molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT jenniferlguerriero molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT romualdobarrososousa molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT tianyuli molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT tessomeara molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT anitagiobbiehurder molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT nabihahtayob molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT jianihu molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT marianosevergnini molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT judithagudo molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT inesvazluis molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT leilanianderson molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT victoriaattaya molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT jihyepark molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT jakeconway molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT mengxiaohe molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT brendanreardon molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT erinshannon molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT gerburgwulf molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT lauramspring molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT rinathjeselsohn molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT iankrop molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT nancyulin molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT annpartridge molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT ericpwiner molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT elizabethamittendorf molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT davidliu molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT eliezermvanallen molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT saramtolaney molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
_version_ 1718378422955147264

Ejemplares similares